Two cases of choroidal osteoma

Choroidal osteoma is a benign, bony tumour of the choroid, which affects otherwise healthy females in the second or third decades of their lives. The tumour is frequently asymptomatic, but rarely can cause neovascularisation of the choroid and be sight threatening. In this report two asymptomatic cases of choroidal osteoma which were detected on routine ophthalmological examination

Eye injury (ocular trauma) in southern Turkey: Epidemiology, ocular survival, and visual outcome

PubMedID: 19190858Purpose To evaluate the epidemiology and outcome of ocular trauma in southern Turkey. Methods Patients referred to the University of Çukurova, School of Medicine, Department of Ophthalmology, with ocular trauma during the last two years were reviewed retrospectively. Age and gender of patients, type of injury, cause of injury, place where injury occurred, initial and final visual acuities, and final outcome were analyzed. Results Medical records of 250 patients (four bilateral injuries), aged between three months and ninety years were reviewed. Ocular trauma mostly occurred between 0 and 15 years and a male preponderance (76.8%) was evident. There were 72% open-globe injuries, corneal and/or scleral penetration being the most common injury type. Metallic objects were the main cause of injury (32.4%). Fifty percent of injuries happened in streets. Closed-globe and self-sealing corneal injuries were found to have the best prognosis in terms of final outcome (57.6% and 57.9%, respectively; P < 0.001 for both). Initial visual acuity was found to be a significant predictor of final visual acuity (P < 0.001). Endophthalmitis was significantly associated with metallic objects (P < 0.005). Conclusion Eye injury is still a common and avoidable cause of blindness. Our findings suggest that any person in the population can be subject to ocular trauma at any time. Prognosis might be challenging. Education, attention, and safety precautions would help in reducing ocular morbidity. © 2009 Springer Science+Business Media B.V

Choroidal thickness changes after intravitreal dexamethasone implant injection for the treatment of macular EDEMA due to retinal vein occlusion

PubMedID: 27870799Purpose: To investigate changes in choroidal thickness after intravitreal injection of a dexamethasone implant for macular edema due to retinal vein occlusion. Methods: Thirty-one eyes of 31 patients, treated with a single dose of a dexamethasone implant for retinal vein occlusion-associated macular edema, were included. Subfoveal choroidal thickness (SFCT) and central macular thickness of the affected eyes were compared with those of the normal contralateral eyes at baseline and 1, 3, and 5 months after injection. Results: The mean SFCT of the affected eyes (296.3 m ± 61.6 m) was significantly higher than that of the contralateral eyes (251.2 m ± 57.7 m; P < 0.001) at baseline. After injection, the mean SFCT was decreased compared with baseline in the treated eyes at months 1, 3, and 5. There was a correlation between SFCT and central macular thickness in the affected eyes at baseline (r = 0.397, P = 0.027). The change in SFCT was not correlated with the change in central macular thickness after injection. In the contralateral eyes, the mean SFCT did not change significantly. Conclusion: Subfoveal choroidal thickness in eyes with macular edema due to retinal vein occlusion was higher than that of the contralateral eyes. Intravitreal injection of a dexamethasone implant was associated with a reduction in the choroidal thickness of the treated eye

To the editor

PubMedID: 25011029[No abstract available

Endogenous endophthalmitis caused by diphtheroid bacillus

PubMedID: 23941569Diphtheroids were generally regarded as nonpathogenic contaminants, but recent clinical studies have emphasized that they may cause serious systemic and ocular disease mostly in patients with underlying medical conditions. In this study we present a case report of acute onset endogenous endophthalmitis associated with heavy growth of diphtheroids on the culture of anterior chamber fluid sample in a 46-year-old man with uncontrolled diabetes mellitus. He did well after appropriate treatment and a functional vision was restored. This case highlights the importance of proper management for the outcomes of patients with endogenous endophthalmitis. It is also significant to be cautious about a life-threatening medical status in a patient with such presentation. © Informa Healthcare USA, Inc

Intravitreal aflibercept for management of subfoveal choroidal neovascularization secondary to angioid streaks

PubMedID: 26458482[No abstract available

TWO CASES of ACUTE ENDOPHTHALMITIS after INTRAVITREAL DEXAMETHASONE IMPLANT INJECTION

PubMedID: 26426482Purpose: To present two cases of acute endophthalmitis after intravitreal dexamethasone implant injection and discuss the management of intravitreal implant-associated endophthalmitis. Methods: Two patients, who underwent intravitreal dexamethasone implant injection for macular edema secondary to diabetic retinopathy in one and branch retinal vein occlusion in the other, were admitted with decreased vision, pain, and redness in their treated eyes, 3 days and 5 days after the injection, respectively. The clinical findings of both patients were consistent with acute endophthalmitis. Results: After obtaining aqueous and vitreous samples, the patients were treated with intravitreal antibiotic injection and topical fortified antibiotics. Both patients revealed favorable clinical response and functional vision was recovered. Conclusion: Intravitreal dexamethasone implant-associated endophthalmitis is an uncommon and a challenging situation. Intravitreal antibiotics may lead to favorable visual outcomes without the need for a pars plana vitrectomy and implant removal in selected cases. Copyringht © by Ophthalmic Communications Society, Inc

Topical mitomycin C for the treatment of conjunctival tumor

PubMedID: 17183195Background: To evaluate the efficacy of topical mitomycin C (MMC) for the treatment of conjunctival tumor in a prospective design. Methods: Nine patients (nine eyes) with conjunctival tumor were studied. The patients received topical MMC 0.04% four times daily by one to six courses. Each course consisted of medication for consecutive 7 days followed by 1 week without medication. Follow-up was conducted on patients for control of disease, and side effects. Results: In 7 patients, the tumor completely disappeared during the mean follow-up period of 24.57 ± 5.94 months (range 18-35 months) with no recurrence. In 1 patient, there was no regression of the tumor, and in 1 patient cessation of the treatment was needed because of an adverse effect of the drug. Conclusion: Topical MMC is effective for the treatment of conjunctival tumor. Longer follow-up and large series are needed to assess the duration of tumor control. Copyright © 2007 S. Karger AG

Efficacy of dexamethasone intravitreal implant for the treatment of persistent diffuse diabetic macular edema

PubMedID: 26968412To investigate the efficiency and safety of a single injection of intravitreal dexamethasone implant in eyes with persistent diffuse diabetic macular edema (DME). In this retrospective study, 25 eyes of 20 patients, who underwent a single injection of intravitreal dexamethasone implant for the treatment of persistent diffuse DME, were reviewed. Main outcome measures included the changes in best-corrected visual acuity (BCVA) and central macular thickness (CMT) from baseline at scheduled visits following injection. The mean BCVA showed improvement from baseline (0.97 ± 0.26 logMAR) at every visit; the difference was significant at day 7 (0.85 ± 0.3 logMAR, p = 0.003), month 1 (0.77 ± 0.32 logMAR, p < 0.001), month 3 (0.77 ± 0.34 logMAR, p = 0.001), and month 4 (0.85 ± 0.31 logMAR, p = 0.014). The mean CMT was significantly lower than baseline (616 ± 132 µm) at day 1 (518 ± 144 µm), day 7 (414 ± 134 µm), month 1 (306 ± 95 µm), month 3 (339 ± 88 µm), month 4 (420 ± 116 µm), and month 6 (494 ± 128 µm) following the injection (p < 0.001, for all). Thirteen eyes on the 4-month follow-up and ten eyes on the 6-month follow-up experienced recurrence of macular edema requiring retreatment. No serious ocular and systemic adverse events were observed. In patients with persistent DME, switching to intravitreal dexamethasone implant injection provides functional and anatomical improvement, and might be an effective therapeutic option for long-standing diffuse DME. © 2016, Springer Science+Business Media Dordrecht